Developer docs
API playgroundTry for free, no card

Search company profiles

Insitro

Full company profile

uuid00004t2

Namestring
Insitro
Legal namestring
Insitro, Inc.
Websiteurl
insitro.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Insitro is an AI-driven drug discovery and development company founded in 2018 by Daphne Koller (co-founder of Coursera, former Stanford professor, former Chief Computing Officer at Calico) and headquartered in South San Francisco. The company operates a full-stack, modality-agnostic drug discovery platform anchored by the Virtual Human Platform, a genetically grounded causal AI engine that integrates multimodal human and cellular data to identify therapeutically validated targets. Platform components include ChemML for small molecule design, ClinML for clinical data phenotyping, CellML for cell-based screening, and POSH (Pooled Optical Screening in Human cells), which combines pooled CRISPR screening with self-supervised Vision Transformers to map gene function at scale. The January 2026 acquisition of CombinAbleAI added physics-informed biologics design capabilities, launching the TherML integrated therapeutic design engine spanning small molecules, oligonucleotides, antibodies, and complex biologics.

The business model is partnership-driven rather than product-driven. Insitro generates revenue primarily through upfront payments, R&D/development/regulatory/commercial milestones, and royalties from co-development agreements with large pharmaceutical and biotechnology partners, supplemented by equity capital from top-tier life sciences and growth investors (a16z, ARCH, BlackRock, Casdin, CPP Investments, Foresite, GV, SoftBank, Temasek, Third Rock, T. Rowe Price). Flagship partnerships include Bristol Myers Squibb (initial $50M upfront and potential $2.1B+ in ALS milestones, plus subsequent $25M, $10M, and $20M payments), Eli Lilly (metabolic diseases and TuneLab ADMET data partnership), and Gilead Sciences (NASH). Active offices span South San Francisco, Tel Aviv (post-CombinAbleAI acquisition), Warsaw, and Kuala Lumpur, with research collaboration in the UK through Moorfields Eye Hospital.

Complementing the partner-funded model is an emerging wholly-owned pipeline: CTRO-1013, an siRNA MASH candidate with anti-fibrotic preclinical data presented in 2026, and the BAT-01 obesity program derived from an AI-enabled brown adipose tissue GWAS. Approximately 200-500 employees support R&D, ML, and partnership operations; the company conducted a 22% workforce reduction in May 2025 to extend cash runway into 2027, reflecting both pre-commercial cost discipline and broader biotech market pressure.

Short descriptiontext

Insitro is an AI-driven drug discovery company that uses machine learning, human genetics, and high-throughput experimentation to identify therapeutic targets and design small molecules, oligonucleotides, and biologics for pharmaceutical partners and a wholly-owned pipeline in metabolic and CNS diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, machine learning therapeutics, computational biology platform, human genetics research, pharmaceutical partnership licensing
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
AI-driven drug discovery
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Partnerships and Licensing
TypeLicensing Royalties
Description

Insitro generates revenue through strategic partnerships with pharmaceutical companies involving upfront payments, milestone payments (research, development, regulatory, and commercial), and royalties on successful products. Partnerships include BMS for ALS (up to $2.1B+ deal value), Eli Lilly for metabolic diseases, and Gilead for NASH therapies.

insitro.com
2Milestone Payments
TypeLicensing Royalties
Description

Non-dilutive funding from pharmaceutical partnerships through research and development milestone achievements. Estimated $150M from non-dilutive partnerships as of recent funding rounds.

insitro.com
3Equity Funding
TypeSubscription Recurring
Description

Capital raised through equity financing rounds from institutional investors including a16z, ARCH, BlackRock, Casdin, CPP Investments, Foresite Capital, GV, SoftBank, Temasek, Third Rock Ventures, and T. Rowe Price. Total approximately $800M raised.

insitro.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1TherML
Description

Therapeutic Machine Learning platform for AI-driven drug design across small molecules, oligonucleotides, antibodies, and complex biologics

insitro.com
+5 more records
Core offering1 text field

Insitro operates an AI-driven, full-stack modality-agnostic drug discovery platform that combines machine learning, human genetics, and high-throughput in vitro experimentation to identify disease targets and design therapeutic candidates across small molecules, oligonucleotides, antibodies, and complex biologics. The company monetizes the platform through strategic co-development partnerships with pharmaceutical companies (BMS, Eli Lilly, Gilead) and Moorfields Eye Hospital, generating revenue from upfront payments, R&D/regulatory/commercial milestones, and royalties. Insitro also advances a wholly-owned pipeline of therapeutic candidates (e.g., CTRO-1013 for MASH, BAT-01 for obesity).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • De-risks drug discovery through human genetics validation at scale
+2 more records
Product overview1 text field

Insitro is an AI therapeutics company offering a unified, full-stack modality-agnostic drug discovery platform. The core offering centers on the Virtual Human™ Platform—a genetically anchored causal AI engine—that integrates multi-modal human and cellular data to discover disease mechanisms. Built upon this foundation are specialized capability modules: TherML™ serves as the integrated therapeutic design engine spanning all modalities (small molecules, oligonucleotides, antibodies, biologics); ChemML™ handles small molecule discovery with ADMET prediction and AI-driven design loops; CellML™ enables cell-based phenotypic screening; and ClinML™ processes clinical data for phenotype generation. The POSH platform provides pooled optical screening capabilities. The January 2026 acquisition of CombinAbleAI extended the platform to include advanced biologics design with physics-informed AI optimization. Pipeline includes therapeutic candidates such as CTRO-1013 for MASH and BAT-01 for obesity.

Product and service8 records
1Virtual Human Platform
CategoryAI Drug Discovery Platform
Description

Genetically anchored causal AI engine that reveals how disease begins, progresses, and can be resolved by integrating the world's largest integrated multimodal corpus of human and cellular data to support target identification across therapeutic areas. Targeted at pharmaceutical R&D partners via strategic co-development agreements.

2TherML (Therapeutic Machine Learning) Platform
CategoryAI Drug Discovery Platform
Description

Integrated therapeutic design engine spanning small molecules, oligonucleotides, antibodies, and complex biologics in a single platform, enabling simultaneous in silico optimization of potency and developability before committing to experimental work. Available through co-development partnerships with pharmaceutical companies.

3ChemML Platform
CategoryAI Drug Discovery Platform
Description

End-to-end small molecule discovery and optimization platform integrating proprietary Quantitative Adaptive Libraries, predictive ADMET modeling, AI-driven design loops, and a large compute cluster of 192 H100 GPUs. Used to discover molecules for partners such as Bristol Myers Squibb.

4CellML Platform
CategoryAI Drug Discovery Platform
Description

Cell model platform for screening genetically supported targets in primary human cells using high-content imaging, transcriptomics, and functional assays to assess cellular phenotypes. Provides the wet-lab foundation for Insitro's ML-driven target validation work.

5ClinML Platform
CategoryAI Drug Discovery Platform
Description

Clinical machine learning platform that analyzes multimodal clinical data including MRI scans, DXA imaging, and biomarker streams to generate high-quality phenotypes for genetic discovery. Used in human cohort analytics and clinical trial design.

6POSH (Pooled Optical Screening in Human cells) Platform
CategoryAI Drug Discovery Platform
Description

Scalable experimental and computational platform integrating pooled CRISPR screening, high-content CellPaint imaging, and self-supervised Vision Transformers to map gene function at scale without relying on predefined biomarkers. Used in-house and through partner programs to identify therapeutic targets.

7CTRO-1013 (MASH therapeutic candidate)
CategoryTherapeutic Candidate
Description

Liver-targeted IRS1 silencing siRNA therapeutic for MASH (metabolic dysfunction-associated steatohepatitis), demonstrating anti-fibrotic signals in preclinical models with effects partially independent of liver fat reduction, advancing toward first-in-human trials. Wholly-owned internal pipeline candidate.

8BAT-01 Program (Obesity target)
CategoryTherapeutic Candidate
Description

Obesity therapeutic target identified through the first AI-enabled GWAS of brown adipose tissue using machine learning-derived phenotypes. In preclinical models, BAT-01 knockdown drives 15% body-weight reduction via peripheral adipose beiging. Internal pipeline program.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

Acquisition of CombinAbleAI platform from Roche/Genentech. The platform provides in silico biology capabilities and multi-omics data integration. Includes engineering team in Israel and computational biology expertise. Represents Insitro's largest strategic acquisition to date.

2Bristol Myers Squibb
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Strategic collaboration for ALS (amyotrophic lateral sclerosis) drug discovery using Insitro's Virtual Human platform and machine learning capabilities. The partnership includes $50M upfront payment with potential milestone and royalty payments totaling over $2.1B. BMS and Insitro will co-develop targets identified through Insitro's platform.

insitro.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

AI foundation model collaboration for ophthalmic image analysis and disease detection. INSIGHT project develops AI models using eye scan data for early disease detection and predictive analytics. Partnership provides access to large-scale clinical imaging data.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Strategic agreement for metabolic diseases including MASLD (metabolic dysfunction-associated steatotic liver disease), MASH (metabolic dysfunction-associated steatohepatitis), and obesity. The partnership leverages Insitro's human genetics platform for target identification and validation in metabolic indications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Partnership for NASH (non-alcoholic steatohepatitis) therapies using Insitro's machine learning-driven drug discovery platform. Collaboration focuses on target identification and validation for liver diseases with unmet medical need.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public AI-driven drug discovery company combining high-throughput biology, automation, and ML to build a wholly-owned and partnered therapeutic pipeline — the closest publicly traded analog to Insitro's platform-plus-pipeline model.

TypeDirect peer
Description

AI-native pharma with a generative chemistry platform producing small-molecule drug candidates for partners like BMS and Sanofi; competes head-to-head with Insitro's ChemML and partnership-driven GTM.

TypeDirect peer
Description

Computational chemistry and physics-based simulation platform serving pharma partners and advancing a wholly-owned pipeline; overlaps with Insitro on physics-informed molecular design (especially post-CombinAbleAI) and platform licensing.

4Isomorphic Labs
TypeEmerging player
Description

Alphabet/DeepMind-backed AI drug discovery company applying AlphaFold-derived models to partnered drug design; competes for the same large-pharma ML-discovery mandates and benefits from Alphabet's compute scale.

TypeDirect peer
Description

AI drug discovery company using knowledge graphs and ML for target identification and clinical development; comparable to Insitro in the target-ID and repurposing segments and competes for similar pharma partnerships.

TypeDirect peer
Description

Pioneer in structure-based small-molecule AI design (AtomNet) with pharma partnerships across multiple therapeutic areas; overlaps with Insitro's ChemML and virtual screening capabilities.

TypeEmerging player
Description

AI-driven small-molecule design company combining graph neural networks with physics; competes with Insitro's ChemML for partnership-driven discovery programs and on generative chemistry quality.

TypeEmerging player
Description

China-based AI + robotics drug discovery company with significant pharma partnerships and a public listing; relevant regional and platform peer to Insitro's modality-agnostic design ambitions.

9Iambic Therapeutics
TypeEmerging player
Description

AI-driven drug discovery company using physics-informed neural networks for small-molecule design; comparable to Insitro's ChemML and broader ML-platform thesis with overlapping partnership-driven GTM.

TypeBroad incumbent
Description

Alphabet-owned life sciences platform leveraging large-scale clinical and biological data, including former Daphne Koller involvement as chief computing officer; adjacent incumbent in the same ML-meets-biology space, and a potential partner or competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Insitro

AI-driven drug discoveryinsitro.com

Insitro is an AI-driven drug discovery company that uses machine learning, human genetics, and high-throughput experimentation to identify therapeutic targets and design small molecules, oligonucleotides, and biologics for pharmaceutical partners and a wholly-owned pipeline in metabolic and CNS diseases.

What Insitro does

Insitro is an AI-driven drug discovery and development company founded in 2018 by Daphne Koller (co-founder of Coursera, former Stanford professor, former Chief Computing Officer at Calico) and headquartered in South San Francisco. The company operates a full-stack, modality-agnostic drug discovery platform anchored by the Virtual Human Platform, a genetically grounded causal AI engine that integrates multimodal human and cellular data to identify therapeutically validated targets. Platform components include ChemML for small molecule design, ClinML for clinical data phenotyping, CellML for cell-based screening, and POSH (Pooled Optical Screening in Human cells), which combines pooled CRISPR screening with self-supervised Vision Transformers to map gene function at scale. The January 2026 acquisition of CombinAbleAI added physics-informed biologics design capabilities, launching the TherML integrated therapeutic design engine spanning small molecules, oligonucleotides, antibodies, and complex biologics.

The business model is partnership-driven rather than product-driven. Insitro generates revenue primarily through upfront payments, R&D/development/regulatory/commercial milestones, and royalties from co-development agreements with large pharmaceutical and biotechnology partners, supplemented by equity capital from top-tier life sciences and growth investors (a16z, ARCH, BlackRock, Casdin, CPP Investments, Foresite, GV, SoftBank, Temasek, Third Rock, T. Rowe Price). Flagship partnerships include Bristol Myers Squibb (initial $50M upfront and potential $2.1B+ in ALS milestones, plus subsequent $25M, $10M, and $20M payments), Eli Lilly (metabolic diseases and TuneLab ADMET data partnership), and Gilead Sciences (NASH). Active offices span South San Francisco, Tel Aviv (post-CombinAbleAI acquisition), Warsaw, and Kuala Lumpur, with research collaboration in the UK through Moorfields Eye Hospital.

Complementing the partner-funded model is an emerging wholly-owned pipeline: CTRO-1013, an siRNA MASH candidate with anti-fibrotic preclinical data presented in 2026, and the BAT-01 obesity program derived from an AI-enabled brown adipose tissue GWAS. Approximately 200-500 employees support R&D, ML, and partnership operations; the company conducted a 22% workforce reduction in May 2025 to extend cash runway into 2027, reflecting both pre-commercial cost discipline and broader biotech market pressure.

Insitro firmographics

Firmographics
Name
Insitro
Legal name
Insitro, Inc.
Website
https://insitro.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
251–500 employees
Short description
Insitro is an AI-driven drug discovery company that uses machine learning, human genetics, and high-throughput experimentation to identify therapeutic targets and design small molecules, oligonucleotides, and biologics for pharmaceutical partners and a wholly-owned pipeline in metabolic and CNS diseases.
Ownership category
akta.pro rank

Insitro industry classification

Industry
Product category
AI-driven drug discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • AI drug discovery
  • Machine learning therapeutics
  • Computational biology platform
  • Human genetics research
  • Pharmaceutical partnership licensing

Where Insitro is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Insitro business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Partnerships and Licensing: Insitro generates revenue through strategic partnerships with pharmaceutical companies involving upfront payments, milestone payments (research, development, regulatory, and commercial), and royalties on successful products. Partnerships include BMS for ALS (up to $2.1B+ deal value), Eli Lilly for metabolic diseases, and Gilead for NASH therapies.
  2. Milestone Payments: Non-dilutive funding from pharmaceutical partnerships through research and development milestone achievements. Estimated $150M from non-dilutive partnerships as of recent funding rounds.
  3. Equity Funding: Capital raised through equity financing rounds from institutional investors including a16z, ARCH, BlackRock, Casdin, CPP Investments, Foresite Capital, GV, SoftBank, Temasek, Third Rock Ventures, and T. Rowe Price. Total approximately $800M raised.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Insitro product offering

Product offering

Core offering

Insitro operates an AI-driven, full-stack modality-agnostic drug discovery platform that combines machine learning, human genetics, and high-throughput in vitro experimentation to identify disease targets and design therapeutic candidates across small molecules, oligonucleotides, antibodies, and complex biologics. The company monetizes the platform through strategic co-development partnerships with pharmaceutical companies (BMS, Eli Lilly, Gilead) and Moorfields Eye Hospital, generating revenue from upfront payments, R&D/regulatory/commercial milestones, and royalties. Insitro also advances a wholly-owned pipeline of therapeutic candidates (e.g., CTRO-1013 for MASH, BAT-01 for obesity).

Product overview

Insitro is an AI therapeutics company offering a unified, full-stack modality-agnostic drug discovery platform. The core offering centers on the Virtual Human™ Platform—a genetically anchored causal AI engine—that integrates multi-modal human and cellular data to discover disease mechanisms. Built upon this foundation are specialized capability modules: TherML™ serves as the integrated therapeutic design engine spanning all modalities (small molecules, oligonucleotides, antibodies, biologics); ChemML™ handles small molecule discovery with ADMET prediction and AI-driven design loops; CellML™ enables cell-based phenotypic screening; and ClinML™ processes clinical data for phenotype generation. The POSH platform provides pooled optical screening capabilities. The January 2026 acquisition of CombinAbleAI extended the platform to include advanced biologics design with physics-informed AI optimization. Pipeline includes therapeutic candidates such as CTRO-1013 for MASH and BAT-01 for obesity.

Differentiator

Problem solved

Functional benefit

Brands

  • TherML: Therapeutic Machine Learning platform for AI-driven drug design across small molecules, oligonucleotides, antibodies, and complex biologics
  • Virtual Human
  • ChemML
  • CellML
  • ClinML
  • POSH

Products and services

  • Virtual Human Platform Genetically anchored causal AI engine that reveals how disease begins, progresses, and can be resolved by integrating the world's largest integrated multimodal corpus of human and cellular data to support target identification across therapeutic areas. Targeted at pharmaceutical R&D partners via strategic co-development agreements.
  • TherML (Therapeutic Machine Learning) Platform Integrated therapeutic design engine spanning small molecules, oligonucleotides, antibodies, and complex biologics in a single platform, enabling simultaneous in silico optimization of potency and developability before committing to experimental work. Available through co-development partnerships with pharmaceutical companies.
  • ChemML Platform End-to-end small molecule discovery and optimization platform integrating proprietary Quantitative Adaptive Libraries, predictive ADMET modeling, AI-driven design loops, and a large compute cluster of 192 H100 GPUs. Used to discover molecules for partners such as Bristol Myers Squibb.
  • CellML Platform Cell model platform for screening genetically supported targets in primary human cells using high-content imaging, transcriptomics, and functional assays to assess cellular phenotypes. Provides the wet-lab foundation for Insitro's ML-driven target validation work.
  • ClinML Platform Clinical machine learning platform that analyzes multimodal clinical data including MRI scans, DXA imaging, and biomarker streams to generate high-quality phenotypes for genetic discovery. Used in human cohort analytics and clinical trial design.
  • POSH (Pooled Optical Screening in Human cells) Platform Scalable experimental and computational platform integrating pooled CRISPR screening, high-content CellPaint imaging, and self-supervised Vision Transformers to map gene function at scale without relying on predefined biomarkers. Used in-house and through partner programs to identify therapeutic targets.
  • CTRO-1013 (MASH therapeutic candidate) Liver-targeted IRS1 silencing siRNA therapeutic for MASH (metabolic dysfunction-associated steatohepatitis), demonstrating anti-fibrotic signals in preclinical models with effects partially independent of liver fat reduction, advancing toward first-in-human trials. Wholly-owned internal pipeline candidate.
  • BAT-01 Program (Obesity target) Obesity therapeutic target identified through the first AI-enabled GWAS of brown adipose tissue using machine learning-derived phenotypes. In preclinical models, BAT-01 knockdown drives 15% body-weight reduction via peripheral adipose beiging. Internal pipeline program.

Quantifiable outcome

  • De-risks drug discovery through human genetics validation at scale
  • +2 more outcomes

Companies that use Insitro

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Insitro technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature7 records

Insitro partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship and core.

  • CombinAbleAI (Roche/Genentech)flagshipStrategic or Co-development Partner · 1 June 2024Acquisition of CombinAbleAI platform from Roche/Genentech. The platform provides in silico biology capabilities and multi-omics data integration. Includes engineering team in Israel and computational biology expertise. Represents Insitro's largest strategic acquisition to date.
  • Bristol Myers SquibbflagshipStrategic or Co-development Partner · 1 January 2023Strategic collaboration for ALS (amyotrophic lateral sclerosis) drug discovery using Insitro's Virtual Human platform and machine learning capabilities. The partnership includes $50M upfront payment with potential milestone and royalty payments totaling over $2.1B. BMS and Insitro will co-develop targets identified through Insitro's platform.
  • Moorfields Eye Hospital / INSIGHTcoreStrategic or Co-development Partner · 1 January 2021AI foundation model collaboration for ophthalmic image analysis and disease detection. INSIGHT project develops AI models using eye scan data for early disease detection and predictive analytics. Partnership provides access to large-scale clinical imaging data.
  • Eli LillyflagshipStrategic or Co-development Partner · 1 January 2019Strategic agreement for metabolic diseases including MASLD (metabolic dysfunction-associated steatotic liver disease), MASH (metabolic dysfunction-associated steatohepatitis), and obesity. The partnership leverages Insitro's human genetics platform for target identification and validation in metabolic indications.
  • Gilead SciencescoreStrategic or Co-development Partner · 1 January 2018Partnership for NASH (non-alcoholic steatohepatitis) therapies using Insitro's machine learning-driven drug discovery platform. Collaboration focuses on target identification and validation for liver diseases with unmet medical need.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Insitro competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology, automation, and ML to build a wholly-owned and partnered therapeutic pipeline — the closest publicly traded analog to Insitro's platform-plus-pipeline model.
  • Exscientia: AI-native pharma with a generative chemistry platform producing small-molecule drug candidates for partners like BMS and Sanofi; competes head-to-head with Insitro's ChemML and partnership-driven GTM.
  • Schrödinger: Computational chemistry and physics-based simulation platform serving pharma partners and advancing a wholly-owned pipeline; overlaps with Insitro on physics-informed molecular design (especially post-CombinAbleAI) and platform licensing.
  • BenevolentAI: AI drug discovery company using knowledge graphs and ML for target identification and clinical development; comparable to Insitro in the target-ID and repurposing segments and competes for similar pharma partnerships.
  • Atomwise: Pioneer in structure-based small-molecule AI design (AtomNet) with pharma partnerships across multiple therapeutic areas; overlaps with Insitro's ChemML and virtual screening capabilities.

Emerging players

  • Isomorphic Labs: Alphabet/DeepMind-backed AI drug discovery company applying AlphaFold-derived models to partnered drug design; competes for the same large-pharma ML-discovery mandates and benefits from Alphabet's compute scale.
  • Genesis Therapeutics: AI-driven small-molecule design company combining graph neural networks with physics; competes with Insitro's ChemML for partnership-driven discovery programs and on generative chemistry quality.
  • XtalPi: China-based AI + robotics drug discovery company with significant pharma partnerships and a public listing; relevant regional and platform peer to Insitro's modality-agnostic design ambitions.
  • Iambic Therapeutics: AI-driven drug discovery company using physics-informed neural networks for small-molecule design; comparable to Insitro's ChemML and broader ML-platform thesis with overlapping partnership-driven GTM.

Broad incumbents

  • Verily (Alphabet): Alphabet-owned life sciences platform leveraging large-scale clinical and biological data, including former Daphne Koller involvement as chief computing officer; adjacent incumbent in the same ML-meets-biology space, and a potential partner or competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Insitro social profiles

Digital presence

Insitro financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Insitro leadership team

Management profile

Number of profiles

Profiles11 records

Insitro subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Insitro funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Insitro M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Insitro

What does Insitro do?

Insitro operates an AI-driven, full-stack modality-agnostic drug discovery platform that combines machine learning, human genetics, and high-throughput in vitro experimentation to identify disease targets and design therapeutic candidates across small molecules, oligonucleotides, antibodies, and complex biologics. The company monetizes the platform through strategic co-development partnerships with pharmaceutical companies (BMS, Eli Lilly, Gilead) and Moorfields Eye Hospital, generating revenue from upfront payments, R&D/regulatory/commercial milestones, and royalties. Insitro also advances a wholly-owned pipeline of therapeutic candidates (e.g., CTRO-1013 for MASH, BAT-01 for obesity).

Is Insitro a public or private company?

Insitro is a private company. It is classified as venture growth investor backed and is currently operating.

When was Insitro founded?

Insitro was founded in 2018. It employs 251 to 500 people.

Where is Insitro based?

Insitro is headquartered in South San Francisco, United States, in the North America region.

How does Insitro make money?

Three revenue lines are on record. Pharmaceutical Partnerships and Licensing is the primary driver. The others are milestone Payments and equity Funding.

Who are Insitro's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Exscientia, Schrödinger, BenevolentAI and Atomwise. Emerging players are Isomorphic Labs, Genesis Therapeutics, XtalPi and Iambic Therapeutics. Verily (Alphabet) is listed as a broad incumbent.

Does Insitro have an API?

No public API is recorded for Insitro.

What industry is Insitro in?

Insitro's product category is AI-driven drug discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireAstraZeneca strikes $40 million AI drug discovery deal with insitroAstraZeneca agreed to pay $40 million upfront to insitro for AI-driven discovery of treatments for liver and heart conditions. The deal includes up to $1.46 billion in milestones and royalties, focusing on MASH and cardiomyopathies. Insitro will use its Virtual Human AI platform to advance targets.EuropaWireTag Archives: AstraZeneca and insitro Launch AI Collaboration to Discover Therapies for Cardiometabolic DiseasesAstraZeneca and insitro signed a strategic drug discovery and licensing collaboration to discover therapies for cardiometabolic diseases. insitro will receive $40 million upfront and may earn approximately $1.46 billion in milestones under the agreement, which gives AstraZeneca exclusive global rights to selected programmes.QuartzAstraZeneca partners with AI biotech insitro on liver, heart drugsAstraZeneca and Insitro signed a drug discovery and licensing deal targeting MASH and cardiomyopathies. Insitro receives $40 million upfront and could earn up to $1.46 billion more, with potential royalties, for a total potential value of about $1.5 billion. AstraZeneca holds sole global rights to any programs that emerge.EuropaWireAstraZeneca and insitro Form AI Drug Discovery Alliance Targeting MASH and CardiomyopathiesAstraZeneca and insitro announced a strategic collaboration to use AI to identify treatment targets for MASH and cardiomyopathies. insitro will receive $40 million upfront and may earn up to approximately $1.46 billion in milestones, with AstraZeneca holding exclusive worldwide rights to selected programmes.European Medical JournalAstraZeneca agrees $40m AI drug discovery deal with insitroAstraZeneca agreed a $40m upfront payment with insitro to develop treatments for liver and heart diseases using AI. The deal targets metabolic dysfunction-associated steatohepatitis and cardiomyopathies, with insitro earning up to $1.46bn in milestone payments and royalties. AstraZeneca will lead clinical development and retain exclusive rights.EIN PresswireAstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership - Pharmaceutical TechnologyAstraZeneca and insitro signed a $1.5B AI-powered partnership to develop drugs for MASH and cardiomyopathies. AstraZeneca pays $40M upfront and up to $1.46B in milestones for exclusive rights, with single-digit royalties. The deal aims to accelerate discovery using insitro's Virtual Human AI platform.Pharmaceutical TechnologyAstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership - Pharmaceutical TechnologyAstraZeneca and insitro signed a $1.5B AI-powered partnership to develop drugs for MASH and cardiomyopathies. AstraZeneca pays $40M upfront and up to $1.46B in milestones for exclusive rights. The deal aims to accelerate discovery using insitro's Virtual Human AI platform.ContractpharmaAstraZeneca, insitro Sign AI Drug Discovery DealAstraZeneca and insitro signed a strategic agreement to use insitro's AI platform for drug discovery in MASH and cardiomyopathies. The deal includes a $40 million upfront payment and up to $1.46 billion in milestones, with AstraZeneca holding exclusive worldwide rights.Nate제약사·AI 기업 협력 확대…아스트라제네카, 인시트로와 최대 2조원 계약 : 네이트 뉴스AstraZeneca announced a partnership with AI startup Insitro to develop treatments for cardiovascular and metabolic diseases using AI to identify disease mechanisms and targets. The deal is worth up to $15 billion, with a $40 million upfront payment and up to $14.6 billion more upon meeting development and commercialization milestones.Analytics InsightAstraZeneca and insitro Sign USD 1.5 Billion AI Drug Discovery PartnershipAstraZeneca and insitro signed a multi-year AI drug discovery partnership targeting liver and heart diseases, with potential payments up to $1.46 billion in milestones. AstraZeneca will pay $40 million upfront and lead clinical trials for advanced programs. The collaboration aims to use insitro's AI platform to identify drug targets for conditions like MASH and cardiomyopathies.